Molecular monitoring of minimal residual disease in patients in long- term complete remission after allogeneic stem cell transplantation for multiple myeloma

Michele Cavo, Carolina Terragna, Giovanni Martinelli, Sonia Ronconi, Elena Zamagni, Patrizia Tosi, Roberto M. Lemoli, Monica Benni, Giorgio Pagliani, Giuseppe Bandini, Sante Tura

Research output: Contribution to journalArticlepeer-review

Abstract

In the present study, we used a polymerase chain reaction-based (PCR- based) strategy to retrospectively analyze the presence of residual myeloma cells in serial posttransplant bone marrow samples obtained from 13 patients in remission after allogeneic hemopoietic stem cell transplantation (allo SCT). For this purpose, patient-specific primers were generated from complementarity determining regions 2 and 3 of the rearranged IgH gene. The level of sensitivity of the PCR-based assay ranged from 1 in 105 to 1 in 106 normal marrow cells. Following transplantation, 9 of 12 patients who attained stringently defined complete remission (CR) remained persistently PCR- for a median of 36 months, and 4 of the patients remained PCR- up to the latest analysis, which was performed at 48, 72, 72, and 120 months, respectively, after allo SCT. None of the patients in the PCR- subgroup experienced a disease relapse, and only 1 of 4 PCR+ patients experienced a relapse. It is concluded that allo SCT has the potential ability to induce sustained serological and molecular CR in selected patients with multiple myeloma. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)355-357
Number of pages3
JournalBlood
Volume96
Issue number1
Publication statusPublished - Jul 1 2000

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Molecular monitoring of minimal residual disease in patients in long- term complete remission after allogeneic stem cell transplantation for multiple myeloma'. Together they form a unique fingerprint.

Cite this